All News #Library
Others
Ubiquigent and Debiopharm team up to advance USP1 inhibitor
27 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
Ubiquigent and Debiopharm Enter Agreement to Support for Debio 0432
26 Mar 2024 //
BUSINESSWIRE
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
11 Mar 2024 //
BUSINESSWIRE
Ubiquigent DUB inhibitor pact survives Bristol-Celgene merger
19 Jun 2020 //
FIERCE BIOTECH
Avidity tops up IPO at $298M; Bristol Myers keeps a Celgene discovery pact alive
17 Jun 2020 //
ENDPTS
Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb
17 Jun 2020 //
BUSINESSWIRE

Market Place
Sourcing Support